Advertisement
With the closing, Novartis assumes ownership of certain dry powder andliquid pulmonary formulation and manufacturing assets, including capitalequipment and manufacturing facility lease obligations. The sale alsotransferred to Novartis approximately 140 Nektar personnel, as well as certainintellectual property and manufacturing methods, including manufacturing androyalty rights to Novartis' Tobramycin inhalation powder (TIP) program.
Advertisement
Nektar continues to own its Bayer HealthCare-partnered program NKTR-061(Amikacin Inhale) and royalties from the Ciprofloxacin inhaled powder program(CIP), also partnered with Bayer HealthCare. In addition, Nektar retains itsNKTR-063 (inhaled vancomycin) program, as well as all intellectual propertyspecific to inhaled insulin.
JPMorgan acted as exclusive financial advisor to Nektar.
About Nektar
Nektar Therapeutics is a biopharmaceutical company developing noveltherapeutics based on its advanced polymer conjugate technology platforms.Nektar's technology and drug development expertise have enabled nine approvedproducts for partners, which include leading biopharmaceutical companies.Nektar is also developing a robust pipeline of its own high-value therapeuticsthat addresses unmet medical needs by leveraging and expanding its technologyplatforms to improve and enable molecules. For more information on NektarTherapeutics, please visit http://www.nektar.com.Nektar Contacts: Jennifer Ruddock Nektar Therapeutics +1 650 631 4954 [email protected] Susan Noonan The SAN Group [email protected] +1 212 966 3650
SOURCE Nektar Therapeutics
